- Omid Farokhzad, Noubar Afeyan, Robert S. Langer
- Cambridge, MA
- Went Public on Sep 20, 2013
- Health Care, Biotechnology
- BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.
Current Team (15)Update
Chief Medical Officer
Board of Directors & Co-Founders
Founer, Board of Directors
Chief Financial Officer
Senior Vice President, Technology, Research and Development
Jan 1, 2010
Senior Vice President, Business Development and Commercial
Jun 1, 2013
Past Team (5)Update
Funding Rounds (5) - $121.8MUpdate
Board Members and Advisors (14)Update
$6 BN russian investment fund
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs,...
Venture capital firm
Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates...
325 Vassar Street
Cambridge, MA 02139
- 09/20/13 -nasdaq.com